Khaled Musallam/LinkedIn
Aug 13, 2026, 11:05
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:
“Pleased to share our latest ‘2026 Update on Clinical Trials in β-Thalassemia,’ published today in the American Journal of Hematology.
It is incredibly fulfilling to reflect on how much the field has advanced since our last update in 2021 with new approvals and an expanding pipeline continuing to reshape the treatment landscape for β-thalassemia.”
Title: 2026 Update on Clinical Trials in β-Thalassemia
Authors: Khaled M. Musallam, Franco Locatelli, Mattia Algeri, Maria Domenica Cappellini, Ali T. Taher

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice